is semaglutide a lifelong medication typically prescribed for Type 2 diabetes; however, it has gained recent popularity as a weight-loss medication. Learn more from Bryan Kuhn, PharmD, DABAT, Clinical Educator at the Banner Quit a GLP-1? Plan to

Description

For reference on class-related adverse effects and warnings, the Summary of Product Characteristics (SmPC) for approved GLP-1 and dual GIP/GLP-1 receptor agonists including Wegovy (semaglutide) and Mounjaro (tirzepatide) are available on the Electronic Medicines Compendium (www.medicines.org.uk/emc)

It contains the semaglutide ingredient as its active component that is included in a group of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists

Quick Answer: Leg pain is not a recognised adverse reaction in the UK Summary of Product Characteristics for Wegovy, though some patients report musculoskeletal discomfort potentially related to rapid weight loss, electrolyte imbalances, or increased physical activity rather than direct drug effects